Nociception
Nociception is the sensory process that provides the signals that lead to pain. This occurs through nociceptors, primary sensory neurons that are activated by stimuli that cause tissue damage. Stimuli can include tissue injury, extremes of heat and noxious chemicals. Unlike other sensory neurons that detect vision or taste, nociceptors are located all around the body, particularly under the skin, however, they are notably absent from the brain.
Nociception Products Targets
- Others (20)
- Nucleoside Transporter (5)
- Glycine Transporter (6)
- GABA (10)
- Cannabinoid Transporter (10)
- Acetylcholine Transporter (1)
- D4 Receptor (12)
- 5-HT7 Receptor (11)
- 5-HT6 Receptor (14)
- 5-ht5 Receptor (2)
- 5-HT4 Receptor (17)
- NK2 Receptor (7)
- NK1 Receptor (15)
- NOP Receptor (21)
- Mu-Opioid Receptors (15)
- Kappa Opioid Receptors (14)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- AMPA Receptor (45)
- GABAA-ρ Receptor (8)
- GABAA Receptor (66)
- GPR55 (8)
- CB2 Receptor (6)
- CB1 Receptor (17)
- Voltage-gated Sodium (NaV) Channels (30)
- Voltage-gated Potassium (KV) Channels (38)
- Voltage-gated Calcium Channels (CaV) (38)
- Neurotensin Receptors (7)
- Glycine Receptors (6)
- Fatty Acid Amide Hydrolase (15)
- Cyclooxygenases (24)
- Bradykinin Receptors (12)
- D3 Receptor (12)
- NK3 Receptor (5)
- Vesicular Monoamine Transporter (4)
- NMDA Receptor (87)
- Kainate Receptor (22)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- Histamine H4 Receptor (12)
- Histamine H3 Receptor (22)
- Histamine H2 Receptor (10)
- Histamine H1 Receptor (17)
- Adrenergic Transporter (23)
- 5-HT Transporter (30)
- NO donors and precursors (9)
- nNOS (5)
- iNOS (11)
- eNOS (1)
- M5 Receptor (2)
- M4 Receptor (3)
- M3 Receptor (4)
- M2 Receptor (5)
- M1 Receptor (8)
- Delta opioid receptor (16)
- Adrenergic α2 Receptor (33)
- Adrenergic α1 Receptor (22)
- Adrenergic β3 Receptor (12)
- Adrenergic β2 Receptor (6)
- Adrenergic β1 Receptor (7)
Products for Nociception - Page 17
- Cat.No. Product Name Information/Activity
-
BCC7847
Sipatrigine
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke.
-
BCC6179
TC-N 1752
1211866-85-1
-
BCN1035
Tetrodotoxin
Tetrodotoxin is a highly selective <b>sodium channel</b> blocker, with <b>IC<sub>50</sub></b> of 33 nM for <b>Nav1.6</b>.
-
BCC2156
Valproic acid sodium salt (Sodium valproate)
Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
-
BCN2609
Vinpocetine
Vinpocetine (Ethyl apovincaminate) is a derivative of the alkaloid Vincamine that blocks voltage-gated Na+ channels. The IC50 value of Vinpocetine on direct IKK inhibition in the cell-free system is 17.17 μM. Vinpocetine is a phosphodiesterase (PDE) inhibitor and inhibits NF-κB-dependent inflammatory responses by directly targeting IκB kinase complex (IKK), and has been widely used for the treatment of cerebrovascular disorders.
-
BCC1048
β-Pompilidotoxin
Slows neuronal Na<sup>+</sup> channel inactivation
-
BCC5078
Rufinamide
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).
-
BCC7928
BIMU 8
Potent 5-HT<sub>4</sub> receptor full agonist
-
BCC4207
Cisapride
81098-60-4
-
BCC7562
CJ 033466
519148-48-2


